Sorafenib, a pan-TKI acting on VEGFR2, VEGFR3, PDGFR-β, and Raf-1 and approved for the treatment of advanced HCC, showed scarce efficacy and disappointing results in the treatment of CCA [74]. Here, FLT4 is linked to hepatocellular carcinoma.